<SEC-DOCUMENT>0001193125-24-005285.txt : 20240109
<SEC-HEADER>0001193125-24-005285.hdr.sgml : 20240109
<ACCEPTANCE-DATETIME>20240109170826
ACCESSION NUMBER:		0001193125-24-005285
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240109
DATE AS OF CHANGE:		20240109

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ambrx Biopharma, Inc.
		CENTRAL INDEX KEY:			0001990550
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-56600
		FILM NUMBER:		24524036

	BUSINESS ADDRESS:	
		STREET 1:		10975 NORTH TORREY PINES ROAD
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 875-2400

	MAIL ADDRESS:	
		STREET 1:		10975 NORTH TORREY PINES ROAD
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	New Ambrx Biopharma Inc.
		DATE OF NAME CHANGE:	20230818

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>d706492ddfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<HTML><HEAD>
<TITLE>DFAN14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ambrx Biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Johnson&nbsp;&amp; Johnson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and <FONT
STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;9, 2024, Johnson&nbsp;&amp; Johnson, a New Jersey corporation (the &#147;Company&#148;),
issued the following email communication to employees of Ambrx Biopharma, Inc. (&#147;Ambrx&#148;) in connection with the Company&#146;s entry into a definitive agreement to acquire Ambrx. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g706492g0109105330311.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ambrx Acquisition | Employee Message to Ambrx Employees</B>&nbsp;<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>From: </B>Jennifer Taubert and John Reed</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subject: </B>A
message from Jennifer Taubert and John Reed at Johnson&nbsp;&amp; Johnson<B>&nbsp;</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date: </B>January&nbsp;9, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ambrx Colleagues, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incredibly excited for both our
companies. Following this week&#146;s announcement, we know you likely have a lot of questions about next steps, and we wanted to start by saying hello and connecting with you as soon as possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are inspired by the work you have done to build Ambrx and advance your pipeline. We share your commitment to discover and develop next-generation therapies
that can transform patient lives. We recognize that Ambrx&#146;s courageous colleagues, pioneering technology platform, and exciting portfolio offer opportunities to tackle some of the greatest challenges in healthcare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson is a leading global healthcare company, built on the values represented in our Credo over the past 80 years. Like you, we recognize
the urgent and unmet patient needs that exist today. In the last decade, we have pioneered numerous innovative medicines, most of these <FONT STYLE="white-space:nowrap">first-and</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class,</FONT></FONT> that have significantly advanced the treatment paradigm in oncology, and beyond. We believe we can build on the groundbreaking science Ambrx has developed and achieve even more together. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to welcoming you to Johnson&nbsp;&amp; Johnson and will be as open and timely in our communications with you as we can. With Ambrx leadership,
we plan for you to meet some of our leaders soon, ask questions and learn more about Johnson&nbsp;&amp; Johnson and our steadfast determination to bring transformational medicines to patients. Until closing of the transaction, however, it is
business as usual, and Ambrx and Johnson&nbsp;&amp; Johnson will continue to operate as separate companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to building a bright future,
together. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warm Regards, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Taubert </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Worldwide Chairman, Innovative Medicine </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Reed, M.D., Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Global Head of
R&amp;D, Innovative Medicine </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Forward-Looking Statements </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains &#147;forward-looking statements&#148; regarding the acquisition of Ambrx Biopharma, Inc. (&#147;Ambrx&#148;). The reader is
cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson&nbsp;&amp; Johnson or Ambrx. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risks and uncertainties include, but are not limited to:
the risk that the closing conditions for the acquisition will not be satisfied, including the risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act or other applicable antitrust laws will not be obtained; uncertainty as to the
percentage of Ambrx stockholders that will vote to approve the proposed transaction at the Ambrx shareholder meeting; the possibility that the transaction will not be completed in the expected timeframe or at all; potential adverse effects to the
businesses of Johnson&nbsp;&amp; Johnson or Ambrx during the pendency of the transaction, such as employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the transaction, including
resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development,
including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory
action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to
patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services
and products; and trends toward health care cost containment. In addition, there will be risks and uncertainties related to the ability of the Johnson&nbsp;&amp; Johnson family of companies to successfully integrate the programs and
employees/operations and clinical work of Ambrx. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A further list and description of these risks, uncertainties and other factors and the general risks
associated with the respective businesses of Johnson&nbsp;&amp; Johnson and Ambrx can be found in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended January&nbsp;1, 2023,
including in the sections captioned &#147;Cautionary Note Regarding Forward-Looking Statements&#148; and &#147;Item 1A. Risk Factors,&#148; and in the company&#146;s most recently filed Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> and the company&#146;s subsequent filings with the Securities and Exchange Commission (the &#147;SEC&#148;), and Ambrx&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
fiscal year ended December&nbsp;31, 2022. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.ambrx.com or on request from Johnson&nbsp;&amp; Johnson or Ambrx. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Johnson&nbsp;&amp; Johnson nor Ambrx undertakes to update any forward-looking statement as a result of new information or future events or
developments, except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Participants in the Solicitation </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson and Ambrx and their respective directors, executive officers and other members of management and employees, under SEC rules, may be
deemed to be &#147;participants&#148; in the solicitation of proxies from stockholders of Ambrx in connection with the proposed transaction. Information about Johnson&nbsp;&amp; Johnson&#146;s directors and executive officers is set forth in
Johnson&nbsp;&amp; Johnson&#146;s Proxy Statement on Schedule 14A for its 2023 Annual Meeting of Shareholders, which was filed with the SEC on March&nbsp;15, 2023, and in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
fiscal year ended January&nbsp;1, 2023, as applicable. Information about Ambrx&#146;s directors and executive officers is set forth in Ambrx&#146;s Proxy Statement on Schedule 14A for its 2023 Annual General Meeting of Shareholders, which was filed
with the SEC on April&nbsp;28, 2023. To the extent holdings of Johnson&nbsp;&amp; Johnson&#146;s or Ambrx&#146;s securities by their respective directors or executive officers have changed since the amounts set forth in such 2023 proxy statements,
such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Additional information concerning the interests of Ambrx&#146;s participants in
the solicitation, which may, in some cases, be different than those of Ambrx&#146;s stockholders generally, will be set forth in Ambrx&#146;s proxy statement relating to the proposed transaction when it becomes available. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Additional Information and Where to Find It </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication may be deemed to be solicitation material in respect of the proposed acquisition of Ambrx by Johnson&nbsp;&amp; Johnson. In connection with
the proposed transaction, Ambrx intends to file relevant materials with the SEC, including Ambrx&#146;s proxy statement in preliminary and definitive form. INVESTORS AND STOCKHOLDERS OF AMBRX ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE
SEC, INCLUDING AMBRX&#146;S PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders of Ambrx are or will be able to obtain these documents (when
they are available) free of charge from the SEC&#146;s website at www.sec.gov, or free of charge from Ambrx on Ambrx&#146;s website at https://ir.ambrx.com. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g706492g0109105330311.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g706492g0109105330311.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 .8# 2(  A$! Q$!_\0
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M=7DMDDZ+$ =W;'/3US3H_&ED^BZEJ+V\\3Z<=MS;. '4UE67_)2-+_[ 0_\
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,14T?@16/_P!XD?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
